Under gemcitabine therapy, the addition of either PX-478, an HIF-1 inhibitor [77] or FRAX597, a PAK1 selective inhibitor [78] augments the antitumor efficacy and stifles pancreatic cancer cell proliferation and migration. The gene discussed is HIF1A; the disease is familial pancreatic carcinoma.